Verastem Oncology: Funding, Investors & Team (Oct 2026)
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.
Verastem Oncology has raised $25.0M across 1 funding round on record, the most recent a Post-IPO Debt of $25.0M announced in Mar 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Verastem Oncology Company Profile and Key Stats
Latest funding round on record: Mar 2022.
Verastem Oncology Funding Rounds
Verastem Oncology Founders and Leadership Team
Contact details for the Verastem Oncology team: 1 of 1 has an email address on file.
Start 14-day free trial →Verastem Oncology Funding Compared to Other Biotechnology Startups
Verastem Oncology's latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Verastem Oncology in Biotechnology and Needham
Companies Similar to Verastem Oncology
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Verastem Oncology Funding FAQs
What does Verastem Oncology do?
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.
How much funding has Verastem Oncology raised?
Verastem Oncology has raised $25.0M across 1 round on record. The most recent is a Post-IPO Debt of $25.0M announced in Mar 2022.
When did Verastem Oncology last raise funding?
Verastem Oncology's most recent funding round on record is a Post-IPO Debt of $25.0M, announced in Mar 2022.
Who is the CEO of Verastem Oncology?
Brian Stuglik is listed as CEO at Verastem Oncology.
Where is Verastem Oncology headquartered?
Verastem Oncology is based in Needham, Massachusetts, United States.
How many employees does Verastem Oncology have?
Verastem Oncology is in the 101-250 employee band.
How does Verastem Oncology's funding compare to other Biotechnology startups?
Verastem Oncology's latest round of $25.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Verastem Oncology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Verastem Oncology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.